| 4101 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
50 |
| 4102 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
53 |
| 4103 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
20 |
| 4104 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
64 |
| 4105 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
66 |
| 4106 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
62 |
| 4107 |
Apheresis |
Autologous |
Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
61 |
| 4108 |
Apheresis |
Autologous |
Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
49 |
| 4109 |
Apheresis |
Allogeneic |
Non-Hodgkin-Lymphoma-Relapse |
Hematology |
2021 |
Standard Therapy |
Germany |
62 |
| 4110 |
Apheresis |
Allogeneic |
Osteomyelitis |
Hematology |
2021 |
Standard Therapy |
Poland |
47 |
| 4111 |
Apheresis |
Allogeneic |
Osteomyelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
69 |
| 4112 |
Apheresis |
Allogeneic |
Osteomyelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
43 |
| 4113 |
Apheresis |
Autologous |
Osteosclerotic Myeloma |
Hematology |
2021 |
Standard Therapy |
Germany |
54 |
| 4114 |
Apheresis |
Allogeneic |
Other Myelodysplastic Syndromes |
Hematology |
2021 |
Standard Therapy |
Poland |
65 |
| 4115 |
Apheresis |
Allogeneic |
Other Myelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
68 |
| 4116 |
Apheresis |
Allogeneic |
Other Myelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
70 |
| 4117 |
Apheresis |
Allogeneic |
Other Myelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
72 |
| 4118 |
Apheresis |
Allogeneic |
Other Plasma Cell Disorder |
Hematology |
2021 |
Standard Therapy |
Poland |
67 |
| 4119 |
Apheresis |
Allogeneic |
Peripheral T-Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
45 |
| 4120 |
Apheresis |
Allogeneic |
Philadelphia-Positive Acute Lymphoblastic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
61 |
| 4121 |
Apheresis |
Allogeneic |
Polycythemia Vera |
Hematology |
2021 |
Standard Therapy |
Poland |
65 |
| 4122 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
71 |
| 4123 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
66 |
| 4124 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
62 |
| 4125 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
53 |
| 4126 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
44 |
| 4127 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
54 |
| 4128 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
65 |
| 4129 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
65 |
| 4130 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
60 |
| 4131 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
66 |
| 4132 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
63 |
| 4133 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
62 |
| 4134 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
64 |
| 4135 |
Apheresis |
Allogeneic |
Prolymphocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
68 |
| 4136 |
Apheresis |
Allogeneic |
Prolymphocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
64 |
| 4137 |
Apheresis |
Allogeneic |
Refractory Cytopenia |
Hematology |
2021 |
Standard Therapy |
Poland |
6 |
| 4138 |
Apheresis |
Allogeneic |
Secondary Acute Lymphoblastic Leukemia From Chronic Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
58 |
| 4139 |
Apheresis |
Allogeneic |
Secondary Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
70 |
| 4140 |
Apheresis |
Allogeneic |
Secondary Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
64 |
| 4141 |
Apheresis |
Allogeneic |
Secondary Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
39 |
| 4142 |
Apheresis |
Allogeneic |
Secondary Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
60 |
| 4143 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2021 |
Standard Therapy |
Poland |
35 |
| 4144 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2021 |
Standard Therapy |
Poland |
58 |
| 4145 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2021 |
Standard Therapy |
Poland |
41 |
| 4146 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2021 |
Standard Therapy |
Poland |
38 |
| 4147 |
Apheresis |
Allogeneic |
Severe Combined Immunodeficiency |
Hematology |
2021 |
Standard Therapy |
Poland |
1 |
| 4148 |
Apheresis |
Allogeneic |
Severe Combined Immunodeficiency |
Hematology |
2021 |
Standard Therapy |
Poland |
1 |
| 4149 |
Apheresis |
Allogeneic |
T-Cell Lymphoblastic Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
26 |
| 4150 |
Apheresis |
Allogeneic |
T-Cell Lymphoblastic Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
37 |
| 4151 |
Apheresis |
Autologous |
T-Cell Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
54 |
| 4152 |
Apheresis |
Autologous |
T-Cell Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
66 |
| 4153 |
Apheresis |
Autologous |
T-Cell Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
66 |
| 4154 |
Apheresis |
Autologous |
T-Cell Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
29 |
| 4155 |
Apheresis |
Allogeneic |
T-Cell-Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
45 |
| 4156 |
Apheresis |
Autologous |
Testicular Cancer |
Hematology |
2021 |
Standard Therapy |
Germany |
33 |
| 4157 |
Apheresis |
Allogeneic |
Β – Thalassemia |
Hematology |
2021 |
Standard Therapy |
Poland |
17 |
| 4158 |
Adipose Tissue |
Autologous |
Gonarthrosis |
Orthopedy |
2021 |
Experimental Therapy |
Poland |
51,1 |
| 4159 |
Adipose Tissue |
Autologous |
Gonarthrosis |
Orthopedy |
2021 |
Experimental Therapy |
Poland |
44,4 |
| 4160 |
Adipose Tissue |
Autologous |
Gonarthrosis |
Orthopedy |
2021 |
Experimental Therapy |
Poland |
35,8 |
| 4161 |
Adipose Tissue |
Autologous |
Internal Damage To The Knee Joint |
Orthopedy |
2021 |
Experimental Therapy |
Poland |
40.9 |
| 4162 |
Adipose Tissue |
Autologous |
Soft Tissue Diseases Related To Use, Overload And Pressure |
Orthopedy |
2021 |
Experimental Therapy |
Poland |
27,5 |
| 4163 |
Placenta blood |
Autologous |
Cerebral Palsy |
Neurology |
2020 |
Experimental Therapy |
Poland |
2,6 |
| 4164 |
Cord Tissue |
Allogeneic – Unrelated |
Covid-19 |
Pulmonology |
2020 |
Experimental Therapy |
Poland |
84,5 |
| 4165 |
Cord Tissue |
Allogeneic – Unrelated |
Acquired Epileptic Aphasia |
Neurology |
2020 |
Experimental Therapy |
Poland |
4,11 |
| 4166 |
Cord Tissue |
Allogeneic – Unrelated |
Acute Graft Versus Host Disease |
Hematology |
2020 |
Experimental Therapy |
Poland |
8,11 |
| 4167 |
Cord Tissue |
Allogeneic – Unrelated |
Acute Graft Versus Host Disease |
Hematology |
2020 |
Experimental Therapy |
Poland |
8 |
| 4168 |
Cord Tissue |
Allogeneic – Unrelated |
Acute Graft Versus Host Disease |
Hematology |
2020 |
Experimental Therapy |
Poland |
2,4 |
| 4169 |
Cord Tissue |
Allogeneic – Unrelated |
Acute Respiratory Distress Syndrome; Covid-19 |
Pulmonology |
2020 |
Experimental Therapy |
Poland |
53 |
| 4170 |
Cord Tissue |
Allogeneic – Unrelated |
Acute Respiratory Distress Syndrome; Covid-19 |
Pulmonology |
2020 |
Experimental Therapy |
Poland |
66,11 |
| 4171 |
Cord Tissue |
Allogeneic – Unrelated |
Adrenoleukodystrophy |
Neurology |
2020 |
Experimental Therapy |
Poland |
8,1 |
| 4172 |
Cord Tissue |
Allogeneic – Unrelated |
Alopecia Areata |
Dermatology |
2020 |
Experimental Therapy |
Poland |
36,6 |
| 4173 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2020 |
Experimental Therapy |
Poland |
53,2 |
| 4174 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2020 |
Experimental Therapy |
Poland |
54,4 |
| 4175 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2020 |
Experimental Therapy |
Poland |
48,1 |
| 4176 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2020 |
Experimental Therapy |
Poland |
64,11 |
| 4177 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2020 |
Experimental Therapy |
Poland |
62,9 |
| 4178 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2020 |
Experimental Therapy |
Poland |
69,1 |
| 4179 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2020 |
Experimental Therapy |
Poland |
52,11 |
| 4180 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2020 |
Experimental Therapy |
Poland |
58 |
| 4181 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2020 |
Experimental Therapy |
Poland |
59,7 |
| 4182 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2020 |
Experimental Therapy |
Poland |
52,7 |
| 4183 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2020 |
Experimental Therapy |
Poland |
62,5 |
| 4184 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2020 |
Experimental Therapy |
Poland |
59,6 |
| 4185 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2020 |
Experimental Therapy |
Poland |
59,1 |
| 4186 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2020 |
Experimental Therapy |
Poland |
58,1 |
| 4187 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2020 |
Experimental Therapy |
Poland |
4,3 |
| 4188 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2020 |
Experimental Therapy |
Poland |
7,1 |
| 4189 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2020 |
Experimental Therapy |
Poland |
8,7 |
| 4190 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2020 |
Experimental Therapy |
Poland |
7,6 |
| 4191 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2020 |
Experimental Therapy |
Poland |
9,11 |
| 4192 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2020 |
Experimental Therapy |
Poland |
4,9 |
| 4193 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2020 |
Experimental Therapy |
Poland |
6,1 |
| 4194 |
Cord Tissue |
Allogeneic – Related |
Autism |
Neurology |
2020 |
Experimental Therapy |
Poland |
8 |
| 4195 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2020 |
Experimental Therapy |
Poland |
7,1 |
| 4196 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2020 |
Experimental Therapy |
Poland |
7,1 |
| 4197 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2020 |
Experimental Therapy |
Poland |
5,1 |
| 4198 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2020 |
Experimental Therapy |
Poland |
9,4 |
| 4199 |
Cord Tissue |
Allogeneic – Related |
Autism |
Neurology |
2020 |
Experimental Therapy |
Romania |
13 |
| 4200 |
Cord Tissue |
Allogeneic – Related |
Autism |
Neurology |
2020 |
Experimental Therapy |
Poland |
10 |